Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of the stock in a transaction dated Wednesday, September 19th. The shares were sold at an average price of $39.81, for a total transaction of $310,518.00. Following the transaction, the chief executive officer now owns 812,613 shares of the company’s stock, valued at approximately $32,350,123.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
NASDAQ:ATRA traded up $0.88 on Friday, reaching $36.42. 389,844 shares of the company’s stock were exchanged, compared to its average volume of 722,945. Atara Biotherapeutics Inc has a 52 week low of $12.65 and a 52 week high of $54.45. The firm has a market capitalization of $1.87 billion, a PE ratio of -9.11 and a beta of 2.54.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.17). Sell-side analysts expect that Atara Biotherapeutics Inc will post -4.58 EPS for the current year.
A number of equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. BidaskClub lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $45.00 target price on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $47.80.
A number of institutional investors and hedge funds have recently made changes to their positions in ATRA. Riverhead Capital Management LLC purchased a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $100,000. SG Americas Securities LLC purchased a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $107,000. Great West Life Assurance Co. Can raised its stake in shares of Atara Biotherapeutics by 100.1% during the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 1,655 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of Atara Biotherapeutics during the second quarter worth approximately $180,000. Finally, Highland Private Wealth Management purchased a new position in shares of Atara Biotherapeutics during the second quarter worth approximately $202,000.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Article: Initial Public Offering (IPO)
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.